Evidence map›Paper›PMID 32973929›Full record

ArticleTherapeutic advances in medical oncology2020

Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70.

Shanshan Gao, Ning Pu, Hanlin Yin, Junhao Li, Qiangda Chen, Minjie Yang, Wenhui Lou, Yi Chen, Guofeng Zhou, Changyu Li and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Shanshan GaoDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ning PuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Hanlin YinDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Junhao LiDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Qiangda ChenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Minjie YangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Wenhui LouDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yi ChenDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Guofeng ZhouShanghai Institute of Medical Imaging, Fudan University, Shanghai, China.
Changyu LiDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Guoping LiDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhiping YanDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Lingxiao LiuDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.
Jun YuDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287, USA.
Xiaolin WangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.
Fudan University · CNZhongshan Hospital · CNSun Yat-sen University · CNJohns Hopkins Medicine · USJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiofrequency ablation (RFA) is widely used in palliative therapy of malignant cancers. Several studies have shown its applicability and safety for locally advanced pancreatic cancer (LAPC). The objective of this study was to modify the current regimen to improve its therapeutic effect.

methodsImmune cell subtypes and related cytokines were quantified to uncover the immune pattern changes post-RFA treatment. Then, high-throughput proteome analysis was performed to identify differentially expressed proteins associated with RFA, which were further validated in

resultsIn preclinical murine models of RFA treatment, no significant therapeutic benefit was observed following RFA treatment. However, the proportion of tumor-infiltrating CD8

conclusionsRFA treatment in combination with mTOR signaling blockade can not only promote tumor immune response, but also restrain residual cancer cell proliferation. Such a combination may be a promising and effective therapeutic strategy for LAPC patients.

Indexed as

heat shock protein 70mammalian target of rapamycinmicroenvironmentpancreatic ductal adenocarcinomaradiofrequency ablation

Identifiers

PMID32973929
PMCPMC7491221
OpenAlexW3086851927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.